Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose equivalence of bevacizumab in first-line ovarian cancer therapy
2023-509659-15-00Phase 4Authorised
- Sponsor
- Medical University of Lublin
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by Medical University of Lublin. Primary endpoints: Objective Response Rate (ORR) to treatment and Progression-free survival (PFS). Planned start Jul 2024; status: authorised.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2023-509659-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509659-15-00.